Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Low doses of the GlaxoSmithKline drug otelixizumab did not preserve the function of the insulin-producing beta cells of the pancreas in those newly diagnosed with type 1 diabetes, according to recent research.
The results of the phase 3 trial – called the Durable Response Therapy Evaluation for Early or New-Onset Type 1 Diabetes, or DEFEND-1 - sends researchers back to the drawing board in an attempt to use otelixizumab, an antibody created specifically to treat type 1 diabetes and other autoimmune diseases, to help maintain insulin function.
http://diabeteshealth.com/read/2014...lixizumab-study-showed-no-beta-cell-benefits/
The results of the phase 3 trial – called the Durable Response Therapy Evaluation for Early or New-Onset Type 1 Diabetes, or DEFEND-1 - sends researchers back to the drawing board in an attempt to use otelixizumab, an antibody created specifically to treat type 1 diabetes and other autoimmune diseases, to help maintain insulin function.
http://diabeteshealth.com/read/2014...lixizumab-study-showed-no-beta-cell-benefits/